About Lumos Diagnostics
Lumos Diagnostics is a company based in Carlsbad (United States) founded in 2017. Lumos Diagnostics has raised $40 million across 3 funding rounds from investors including Planet Innovation, Perennial Partners and Ellerston Capital. Lumos Diagnostics operates in a competitive market with competitors including Access Bio, SD Biosensor, Fluxergy, Module Innovations and DxGen, among others.
- Headquarter Carlsbad, United States
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Lumos Diagnostics Holdings Limited
-
Annual Revenue
$12.5 M (USD)12.72as on Jun 30, 2025
-
Net Profit
-$7.24 M (USD)15.41as on Jun 30, 2025
-
EBITDA
-
Total Equity Funding
$40 M (USD)
in 3 rounds
-
Latest Funding Round
$20 M (USD), Post-IPO
Mar 26, 2026
-
Investors
Planet Innovation
& 2 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Lumos Diagnostics
Lumos Diagnostics is a publicly listed company on the ASX with ticker symbol LDX in Australia, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Lumos Diagnostics
Unlock access to complete
Unlock access to complete
Funding Insights of Lumos Diagnostics
Lumos Diagnostics has successfully raised a total of $40M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $20 million completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Post-IPO — $20.0M
-
First Round
First Round
(05 Feb 2020)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2026 | Amount | Post-IPO - Lumos Diagnostics | Valuation |
investors |
|
| Oct, 2020 | Amount | Series B - Lumos Diagnostics | Valuation | Ellerston Capital , Perennial |
|
| Feb, 2020 | Amount | Series A - Lumos Diagnostics | Valuation | Planet Innovation |
|
Investors in Lumos Diagnostics
Lumos Diagnostics has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Planet Innovation, Perennial Partners and Ellerston Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Diversified investment management services are provided by Ellerston Capital.
|
Founded Year | Domain | Location | |
|
Diversified asset management services are provided in Australia.
|
Founded Year | Domain | Location | |
|
End-to-end healthtech product development and manufacturing services are offered.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Lumos Diagnostics
Financial Statements - Lumos Diagnostics
Lumos Diagnostics Comparisons
Competitors of Lumos Diagnostics
Lumos Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Access Bio, SD Biosensor, Fluxergy, Module Innovations and DxGen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
In vitro rapid diagnostic tests, biosensor, and molecular diagnostic products for diagnosis of infectious diseases.
|
|
| domain | founded_year | HQ Location |
Biosensors for point-of-care diagnostics are developed by SD Biosensor.
|
|
| domain | founded_year | HQ Location |
Provides diagnostic devices and software for clinical and veterinary point-of-care testing.
|
|
| domain | founded_year | HQ Location |
Diagnostics strip for bacterial detection
|
|
| domain | founded_year | HQ Location |
Point-of-care diagnostic products for diabetes and tuberculosis are provided.
|
Frequently Asked Questions about Lumos Diagnostics
Lumos Diagnostics was founded in 2017 and raised its 1st funding round 3 years after it was founded.
Lumos Diagnostics is headquartered in Carlsbad, United States. It is registered at Carlsbad, California, United States.
Sacha Dopheide is the current CEO of Lumos Diagnostics.
Lumos Diagnostics is a funded company, having raised a total of $40M across 3 funding rounds to date. The company's 1st funding round was a Series A of $15M, raised on Feb 05, 2020.
Annual revenue of Lumos Diagnostics is $12.5M as on Jun 30, 2025.
Lumos Diagnostics offer a range of diversified diagnostic products. Lumos platform includes assays, readers, cartridges, and software. Their assays include lateral flow and microfluidics to immunoassay and molecular methodologies. Lumos develops disposable assays suitable for assay test strips and development of custom assay specific analysis algorithms. Th company also has handheld and benchtop readers. The company makes POC cartridge technologies, from lateral flow through to microfluidics. The company has a cloud platform capturing information on device location, test usage, results and associated patient metrics.
Lumos Diagnostics's top competitors include Access Bio, SD Biosensor and Module Innovations.
Yes, Lumos Diagnostics is publicly traded on ASX under the ticker symbol LDX.
Lumos Diagnostics has 3 investors. Key investors include Planet Innovation, Perennial Partners, and Ellerston Capital.
The ticker symbol of Lumos Diagnostics is LDX on ASX.